4 results
To define the recommended phase II mean*lung dose (MLD) to treat peripheral stage II or III NSCLC using SABR for the primary tumor and CFRT for the mediastinal lymph nodes while given concurrent chemotherapy.
Primary Objective: To compare overall survival (OS) of subjects randomized to ipilimumab in addition toplatinum and etoposide (Arm A) to that of subjects randomized to placebo in addition to platinum andetoposide (Arm B) in subjects with newly…
The most important questions of this phase III trial is:Can adaptive high dose radiotherapy improve loco-regional control without increase of toxicity?
Phase I study to investigate safety of the combination indomethacin and two platinum-based chemotherapy regimens in patients with advanced cancers.